Biobank Oversight

The BSR oversight structure includes two independent committees, a Biobank Advisory Committee (BAC) and a Utilization Committee (BUC). The BAC serves to evaluate resource utilization and inform the development of strategic initiatives, while the BUC reviews all investigator requests to ensure that BSR samples are disbursed fairly, responsibly, and facilitate impactful research that aligns with Wilmot priorities. These committees are comprised of diverse representation spanning Wilmot leadership, programmatic research, community outreach/engagement (COE), diversity/equity/inclusion (DEI), and human research compliance (RSRB, PRMC).

BAC Members

• Minsoo Kim, PhD (CM Research Program)
• Michelle Janelsins-Benton, PhD, MPH (CPC Research Program)
• Darren Carpizo, MD, PhD (GEM Research Program)
• Lainie Ross, MD, PhD (Bioethics)
• Allison Magnuson, DO (DEI)
• Charles Kamen, PhD, MPH (COE)
• Helen Peck, RN, MA, OCN, CCRP (CTO)
• Richard Burack, MD, PhD (Clinical Pathology)
• Richard Moore, MD (PRMC)
• Omar Aljitawi, MBBS (Medical Oncology)
• Michelle Giglio, CCRP, CIP (RSRB)
• Gabriel Pellegrino (CCAC)

BUC Members

• Darren Carpizo, MD, PhD (CM Research Program)
• Michelle Janelsins-Benton, PhD, MPH (CPC Research Program)
• Minsoo Kim, PhD (CM Research Program)
• Richard Burack, MD (Clinical Pathology)
• Francisco Cartujano, MD (COE)
• Deepak Sahasrabudhe, MD (PRMC)